Flagship Pioneering's AI-Focused Biotech Companies Valo and Montai Merge

Valo Health and Montai Therapeutics, AI-focused biotech companies within Flagship Pioneering, have come together to merge their drug discovery platforms and pipelines under the Valo umbrella. With the merger, the two companies' existing partnerships and early-stage development projects will continue under a single roof.

Founded in 2020 by Flagship Pioneering with approximately $100 million in financing, Valo aims to accelerate drug development in oncology, neurodegenerative, and cardiovascular fields using artificial intelligence. Launched in 2022 with a $50 million seed investment, Montai runs preclinical programs for immunological and respiratory conditions, alongside its phase 1 oral NRF2 agonist MTAI-1025 for ulcerative colitis. The financial or structural specifics of the merger are being kept confidential.

Following the merger, the company will continue to be led by Valo CEO and Flagship CEO Partner Dr. Brian Alexander. Alexander stated that this merger brings together complementary platforms, a growing pipeline, and bioventure partnerships under one roof. Montai CEO Margo Georgiadis noted that the partnership will enable the platform's application across broader therapeutic areas, including immunology and inflammation. The companies have previously collaborated with large-scale global names such as Merck KGaA, Pfizer, Novo, Charles River Laboratories, and NVIDIA.